OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Docusign Envelope ID 42E7C64E-386944C1-8361-66ED4F05CE20 PWlrolA¢fvocury & Referrul se￿ ANNUAL REPORT & FINANCIAL STATEMENTS For the Year Ended 31 December 2025 One Call. Expert Support. Better Outcomes. Registered Charity Number- 1152340

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD 1 2025 REFERENCE & ADMINISTRATIVE DETAILS REGISTRATION CONTENTS Registered company no. 08321795 Registered charity no. 1152340 Trustees, annual report (incorporating thè Dirtetors, Rèport)

19 REGISTERED OFFICE Message from the trustees New BLJrlington House 1075 Finchley Road London NW11 OPU 2025 at a glan Our ambition What we do TRUSTEES Networking Rabbi Hershel Grunfeld Mr Jacob Herzka Mr Pin¢has Weinberger Research Referrals Advocacy 10 AUDITORS Cohen Arnold New Burlington House 1075 Finchley Road London NW11 OPU Diagn05tics 11 Support 12 Fact5 & figures 13 Our specialist divisions 14 BANKERS Oncology division 15 Metro Bank PLC Holborn Branch (Head Office) 1 Southampton Row London WC1 B SHA Achievement5 & luture plans 16 Support & accountability 17 Goveman￿ & financial review 18 ORGANISATION DETAILS Ttustees, responsibilitie5 & approval 19 MARS | Medical Advocacy & Referral Service Unil 15 Grosvenor Way. London E5 9ND 020 3322 8586 www.marsorg.com mail@marsorg.com Independent auditorfs report 2(￿24 Stalement of financial activities 25 Stalement of financial position 26 Stalement of cash flows 27 Not8S to the financial stat8m8nts Thank you 36 MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 A MESSAGE ,. FROM THE TRUSTEES 2025 has been another year of meaningful progress for MARS. Through compassionate advocacy, practical support and strong partnerships, we have continued to help patients and families navigate some of the most complex medical challenges. We work closely with leading UK hospitals and local doctors, connecting patients with the right specialists and resources at the right time. This collaboration helps to improve access to advanced treatments. ensuring families receive the best POSStble guidance and care. Our commitment to research remains central to our work, We SupFY)rt and promote innovative medical research and clinical trials. helping to bring new treatment options within reach for the patients we supporL 66 Raising awareness is also vital. By sharing trusted information and real patient stories. we help more people in our community understand their options and feel better prepared when facing a medical crisis. We help patients and their families navigate complex medical decisions, connecting them with the right specialists and supporting them at every stage. None of this would be possible without the dedication of our supporters. medical partners and the wider community. Together W￿ are making a real difference, giving patients and families hope, knowledge and a clearer path forward. MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 2025 AT A GLANCE 01 Stronger links with UK hospitals and local doctors We have deepened our relationships with leading UK hospitals and local dixtors, building trusted networks that help patients access the right specialists faster and navigate complex medical systems bwth confidence ar4J SUP[￿. 02 More health research and training We liave suppoited a wider r"aiige of medical researcli and clinical trials, and helped to fuid specialist training and knowledge exchange, Ensuring patI￿ts benefit from th) latest innovations and best practice in care. il. 4119" 03 Greater awareness in the community We have expanded our community outreach, tharing trusted information through events, schools, synagogues and dig￿31 channels, so that more people understand tIE importance of being prepared for a ¥TE￿lia1 crisis aiid kiKw wI￿re lo Lurri lor guidqjflce. 04 More global medical opinions We have helped patients obtain expert medical opinions from world-leading specialists In the UK. across Europe, the United State5 arld across the globe, providirvJ access to internat￿nal expertise when it can make a critical difference. 05 Expanded support for patients and families We have provided more ￿rSOnalISed, ongoing support throughout the medical journey. offering practical guidance, reassurance and 3 trusted point of contact for patients and their families when they need it most. MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 OUR AMtIITION MARS was established in 2012 by Rabbi Hershel Grunfeld after witnessing the confusion, stress and uncertainty families can face following a medical crisis. i* He saw how overwhelming it can be to navigate complex medical systems, make urgent decisions and find the right specialists at a time when families are already under enormous emotional pressure. Today, MARS guides patients and families through complex medical situations, connecting them to the right experts and resources with compassion, discretion and practical support. Our ambition is to give every patient access to the most advanced care available, enabling the best possible outcome. IA MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 WHAT 00 Expert guidance. Practical support. Better outcomes. MARS provides a comprehensive range of services to help patients and families navigate complex medical journeys. We work quickly, discreetly and compassionately, connecting people to the right experts and resources when they need them most. Networking Research We connect patient5 arvj famil with leacling specialists and centres ol excellence. localty and internationally, through our trusted global network. We research the latest 11 treatments. clinical trials and medical innovations. providing up.to.date. evidence-based information tailored to each patient's condttion. Referrals Advocacy ooo We identify arKI facilitate access to the most appropriate coiisultants and medical teams, ensuring patients are seen by the right experts as quickty as possible. We a&4ocate on behalf of patients and families, hetping to remove barriers. liaise wtth healthcare providers and ensu palients. needs are understoc and prioritised. coi Diagnostics Support Wè help arrange and ex￿lte vital tests, scans and specialist diagnostic investigations, ensuring accurate and timpjy results to inform the best treatment decisions. We provide ongoing. personal supwrt thrwghout the medical ioumey. offeriro practtcal guidance. reassurance and a trusted point of contact for patients and their families. RAISING AWARENESS IN THE COMMUNITY MARS is comrnitted to faising awareness abwt i mpNtsrxe of bwng prepared fof a medical crisis. We educate ttrectynmunity on valL* ofprivale Insura￿¢, helpiry families U￿tand t￿11 ¢Jptions ¥1 Ihe pwof miTrd il can provKIe. We also promote wider medical awareness, sharing trusted information and reSoUr￿S to help our community make infomed decisions about their health and wellbeing. MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386944C1-8361-66ED4F05CE20 NETWOR IING MARS has built strong relationships with UK hospitals, the NHS, private specialists and local doctors. creating a trusted network that ensures patients can access the right experts and the most suitable care for their individual needs. Through these relationships. MARS helps people find appropriate specialists. obtain second opinions and timely treatment. with the support and guidance they need. Local Dortors UK Hospitals & Specialists International Expertise Better Access Strong relationships with trusted local doctors in our communities Acce5S to leadirg NHS arrfl private specialists across theUK Seeking expert medical opinions from Europe, the USA arKI across the globe Helping patsents access the right specialists, secorKI Opini¢￿s and timely care EUROPE Leading centres and global expertise USA UK World-renowned hospitals and specialists NHS & t)rivate GLOBAL Access to expert opinions from across the world MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386944C1-8361-66ED4F05CE20 RE >EARCH In-depth medical research is central to the V￿Ork we do. MARS gathers and reviews medical records, explores treatment options. seeks global expert opinions and keeps abreast of emerging developments to provide the most current and advanced guidance for our patient& In 2025. we continued to deepen our connections with UK hospitals and international experts. ensuring we stay up to date with advances in treatment, ¢linic81 trial4 and special¢￿t kriowl¢d9Cp 40 wc Gun 4UPPQrt complex and rare cases with the latest evidence and expertise. OUR RESEARCH PROCESS Q 881 Explor• Seek Expert Ild Expwtl We coited ¥rKI review We research ar We re¥h out to We SW infeAnd Our r•seard) is In 2025. we drt•led medical compa￿ treat1￿nI specialists in the UK bout emening Particulady ￿luable strenytrned our cord tsst rLtysuIÈs OPiw)ns, considering arKI internatio1￿Y trÈ8trM)ts, dinal forw*￿tr￿ comFSex global connect¥ons d reports io build the most suitable fof addiiional lriaLsaThJ the cws. whère io furtlier develop a complrfe pcturfr. apprts¥hes lor pefspectNes vthen medical adva¢)¢￿ speoalis¢ knovAed9e our Spec￿1151 exh patlent. inr)ovatwe kn￿ledge and iivtWCJf esserfiaL 66 My obiding interest in MARS. ond my willingness to gwe time to it and support it, 15 because it s there for potient benefit. Irrespective of where someone lives. where someone comes from or what their bockground is, they should alwoys have occess to the best medicol odvice ond the best medicol core. And becouse that s not olwoys the cose, we need orgonisotions thot enoble potients to receive that. To my mind the MARS organisation is exactly thot. Professor Kevln Harrlngton Professor of Biological Cancer Therapies at The Institute of Cancer Research 99 MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 REFERRALS. MARS connects patients to the right specialists quickly and sensitively. based on their medical condition, the expertise required, location, urgency and the family's circumstances. Our experienced team works closely with patients, families and treating doctors to identify the most appropriate specialists and services. arrange appointments. obtain expert opinions. coordinate consultations and guide each patient to the most suitable rr*dical pathway. HOW WE MAKE THE RIGHT I IVNS UNDERSTAND THE PATIENT'S NEEDS We take time io unuerstand the m¢di¢al conditw, experttse required location, wgerq and the family& personal circumstance& IDENTIFY THE RIGHT SPECIALIST We match each patient with the most suitable specialist, based on their specific condition, experience and access lo the latest Irealments. ARRANGE APPOINTMENTS We liaise directly with spechllists and hospitsls to . secure timely appointments. ofien expediting access ' when urgenl care Is fequired. OBTAIN EXPERT OPINIONS We help palients access second opinions and multtd55ciplinèry input when needed. providing confidence in their diagnosis and ireatment options COORDINATE THE PROCESS The right specialist. At the right time. For the best possible outcome. We manage communication between patients, specialists and hospitals. ensuring Information is shared, ￿$￿Its are obtained and consuliations are wdl cO￿dinated. GUIDE TO THE BEST PATHWAY Wo Iiravide cloai. nl)Jèctive giJi(lance to Ihe most suitable medKal pathway. wheiher that invdve5 further testing. specialist irealff￿t. suryJery or oryoing cafe. MARS I ANNUAL REPORT 2025

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 ADVOCACY I MARS supports, informs and empowers patients and families at every step, helping them understand their options, navigate complex systems and feel confident in the decisions they make. Our team wovides clear, impartial information and practical direction. ensuring patients can ask informed questions, communicate effectively with medical providers and access the support they need throughout their healt￿are journey. HOW WE SUPPORT rr ILIES CLEAR. RELIABLE INFORMATION We explain medical conditions, tr&atmwt options and next steps in plain language, so patients and families can make informed decisions. SUPPORT AT EVERY STEP We are here to Ilsten. answer questions and provide reassurance frorn the first call through to treatment nd beyond. 66 It is o privilege to work with Rabbi Grunfeld and MARS. I have always found that MARS is committed to providing the highest standard of care. They support f(7milies at a time of need when there can be great anxiety and uncertainty. Rabbi Grunfeld takes time to understand the complexities of each individual case to be able to provide insightful advice cnd guidance. HELP YOU ASK THE RIGHT QUESTIONS le help palionts prepare lor COnSLltations, with guidarte on the questicms to ask and the informatK)n to request NAVIGATE COMPLEX SYSTEMS le explaiii how the IEalthcare systeNI works, hdp with referrals and reoire the barriersthat can de￿Y acce55 to Core. ADVOCATE ON YOUR BEHALF We commUn￿te with medical providers. ensure patient needs are understood and help resolve issues when additional SUPFX)rt is required. GUIDANCE FOR COMPLEX DECISIONS le proijide IndependLI"It, expert advice vvlien lacing difficult choices. helping patients consider risks, benefits and alternative opti¢y15. Mr Pranav Pandya Consultant in Fetal Medicine, Director of Fetal Medicine, UCLH HOSPITAL COORDINATION We liaise with h05Pltals and specialist team5 to keep treatment on track, coordinate appthntments and ensure a smooth pathway of care. MARS I ANNUAL REPORT 2025 10

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 DIAGNOSTICS,, Faster answers. The right support. A clearer path forward. MARS helps patients access urgent diagnostics, spectalist consultations and the assessments they need, when they need them. We work to remove barriers, including providing financial assistance where necessary, to ensure patients can access essential investigations and stabilize their path to treatment. Through rapid access and expert review. we help patients get answers faster. enabling them to make informed decisions and move forward with clarity and confidence. URGENT DIAfjN05TICS SPECIALIST A55E55MENT5 Rapid ac￿5 to essentiaE scans. tests afK* investigatic￿S wlien time mattefs most. Comprehensive assessments to confim diagnosis and guide treatment option SPECIALIST CONSULTATIONS FINANCIAL ASSISTANCE A£￿5$ to leading specialists across a wide range of rnedical condttions. Support with costs where needed. helping patients access vital investigations and services. EXPERT REVIEW A CLEARER PATH FORWARD Independent review of results and repyts to ensure the r¥Jht diagrmxis aKI next st Helping patients move ahead with clarity. confidence and the right support in place. MARS I ANNUAL REPORT 2025 11

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 -SUPPORT Patients. Families. Always alongside. MARS supports patients and their families throughout the entire journey. From the first call to ongoing care, we provide emotional support, practical direction and coordination help, ensuring no one has to navigate complex medical challenges alone. EMOTIONAL SUPPORT A listening ear and compassionate guidance for patients and families during challenging times. PRACTICAL DIRECTION Clear, trusted information to help families understand options and make confident decisions. ONGOING CONTACT Regular check-ins and continued support, so patients and families never feel alone. COORDINATION SUPPORT Helping to link appointments, share information and work with providers for a smoother journey. AWARENESS MARS helps raise awareness of private medical insurance and other important rnedical issues in the community, so families can stay inf0m￿d and up to date. Trusted Information Community Education Keeping Families Informed MARS I ANNUAL REPORT 2025 12

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 FACTS & FIGURES In 2025, MARS continued to make a real difference, ensuring more patients received the urgent diagnostics and specialist consultations they needed, when they needed them. 300 30 Calls every day Resolute staff 11 3,461 17 402 New cases in 2025 Medical divisions Emergency diagnostics and consultations funded 12 ••. Oncology divisions One Ca//. Expert Support. Beffer Outcomes. MARS I ANNUAL REPORT 2025 13

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 OUR SPECIALIZED DIVISIONS MARS funds emergency diagnostics. consultations and treatment across a wide range of medical specialties. ensuring patients have fast access to expert care when it matters most. Cardiology Complex Pediatrics Critical Care Dermatology Endocrinology ENT Fetal Medicine Gastroenterology Hematology Neurology OB-GYN Ophthalmology Orthopedics Renal & Urology Respiratory Rheumatology Surgical MARS I ANNUAL REPORT 2025 14

Docusign Envelope ID". 42E7C64E-386944C1-8361-66ED4F05CE20 ONCOLOGY DIVISION EXPERT GUIDANCE. ADVANCED CARE. BEThER OUTCOMES. Oncology is a major and specialist division within MARS, providing expert care for a wide range of cancers and complex conditions. We bring together leading specialists to offer advanced diagnostics. personalised treatment plans, second medical opinions. and coordinated care across our network. Our work includes cutting-edge research, access to innovative treatments. and ongoing support for patients and their families. Through close links with UK hospitals and international medical experts, we help ensure every patient receives the right guidance, at the right time, wherever they are in their cancer journey. 12 ONCOLOGY DIVISIONS Breast Oncology Gastrointestinal OnGology Neuro-oncology Dematologic Oncology Gynecologic Oncology Ocular Oncology Hematologic Oncology Head and Neck Oncology Pediatric Oncology Soft Tissue and Sarcoma Oncology ThoraGiG OnGology Urologic Oncology Specialist care. Global expertise. Support for patients and families. MARS I ANNUAL REPORT 2025 15

Docusign Envelope ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 2025 ACCOMPLISHMENTS In 2025, MARS made significant progress in oncology and across our wider work, helping more patients access expert care and support, and continuing to advance research and innovation. STRONGER LINKS WITH UK HOSPITALS MORE RESEARCH AND TRAINING GREATER AWARENESS IN THE COMMUNITY Buslt closer relationships with leading UK hospitals and local doctors to improve access to specialist care and faster pathways for patients. Expanded cancer research activity and provided more specialist training for doctors and healthcare professionals. Increased awareness about cancer and the medical needs of patients through community engagement and education. EXPANDED PATIENT AND FAMILY SUPPORT SOFTWARE UPDATES AND DATA PROTEcfioN Continued to enhance our systems and software to meet modern healthcare needs and improve patient support and Case Coordination. MORE GLOBAL MEDICAL OPINIONS Strengthened practical. emotional and informational support for patients and their families at every stage. Supported more international medical opinions where needed. helping patients access world-leading expertise and tr•atment options. LOOKING AHEAD 2026-27 We will continue to build on this progress. with a clear focus on expanding our oncology work and further strengthening the support we provide. CONTINUED DEVELOPMENT OF ONCOLOGY RESEARCH INTO GENETICS DEEPER CARDIAC OEVELOPMENT STRONGER SUPPORT SERVICES ONGOING somvARE UPDATES CortiNe to athance tyjr cardiJ¢ work lo yjpport palients with compFex c8ncer and cardiovascular Keop deN*lo5Yry Our Systems and tec1r￿o9Y lo enhance patient supp)rt. data proiection and case coordinatio GTQIV &nd FurthAr strnFv3th•n 0￿0￿)Y dlvi5ion research into cancer to ieath rr￿e patsents genet￿5 and d Ixitc¢)rres ￿rsOnalIsed treatment ¥pproache& Enh￿e the raTh of services for pabents and famil￿ wtih focus ￿ efWti(x￿I MARS I ANNUAL REPORT 2025 16

Docusign EnvelopÈ ID". 42E7C64E-386944C1-8361-66ED4F05CE20 CONTINUED SUPPORT & ACCOUNTABILITY l Ded icated caseworkers omplex cases and clinical trials Cases involving several teams or limited conventional options may require wider research, multiple opinions, multidisciplinary planning and exploration of appropriate clinical trials. Long-temi and complex cases can require sustsined contsct. MARS assigns caseworkers lo help families navigate appointments, decisions, communications and ongoing Care. ospital liaison and urgent advocacy Hospital emergencies do not follow office hours. MARS has described round-lhe-clock support, liaison with medical teams and advocacy for patients with medical, cultural and practical needs. Interpretation and cultural understanding MARS helps explain complex terminology, address language barriers and communicate individual religious and cultural requirements to healthcare professionals. Medical records and technical guidance The team helps families request previous scans, lest results and medical reports, and navigate patient portals, remote consullalions, digital fomis and information sharing. om-Tov clinics Free, urgent GP walk-in SeNi￿S for Yom Tov in Stamford Hill and Golders Green. ransfers and practical coordination For patients needing care al another hospital or overseas, MARS helps coordinate medical and travel arrangements, clinical handovers and associated logistics where appropriate. ommunity education and training The estsblished programme includes private medical insurance awareness, wider health information, professional learning, medical conferences and community medical training. iagnostics and financial assistance In selected urgent or potentially life-threatening cases, MARS has helped patients access private investigations or specialist opinions while also coordinating ongoing NHS care. Evaluation and feedback Feedback from patients, medical professionals and community leaders helps MARS refine ils work. Complaints, queries and feedback are recorded sensitively, recognising patient privacy and the pressures of illness. MARS I ANNUAL REPORT 2025 17

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG LTD TRUSTEES, ANNUAL REPORT. YEAR ENDED 31 DECEMBER 2025 STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document The ¢h)riiy is controlled by its governing document, its memorandum and articles of associatiL)n, and constitutes a limited company, limit¢d by guarant¢¢, as d¢fin¢d by Companics A¢t 2006. Recruitment and appointment of new trustees It is not currently the intention of the trustees of the charity to appoint new trustees. Should this situation change in the future, the trustees will apply suitable recruitment and training procedures. Risk Management The trubtees have identified and reviewed the major risks to which the charity is exposed, in particular those related to the operations and finance of ihe charity, and are saiisfied that systems are in place to mitigate ihose risks. Publlc beneflt Tlie tTUStees confiTm that they hdve iefetred to the ¥uiddnce Lontrdined in the Chdtity Cuminission's general ¥uiddrice ori public benefit. when reviewing the charity's aims and objectives, and in planning future activities and setting grant making policy for the year. MARS selves people fiom ethnic ininority cominui)ities, ftscusing paiticularly, but not exLlusively, on the Orthodox Jewish Community. This community has unique religious and culrural needs that may be unfamiliar to the medical world. This community also includeg recent immigrants to the UK, meaning that both the language and the culture are unfamiliar to thcm. Geographically, we are based in London, but we receive calls from all over England and have liaison officers located in other areas of the UK such as Essex, Manchester and Gateshead. FINANCIAL REVIEW The financial position of the Charity is satisfactory. Incoine and donations aggtegate £1,728,031. Total resouiLes expended were £1,727.803 resulting in a net surplus of £228 for the year and toial reserves of £384.258 (2024.. £384,030). DuTiil¥ the year, the LhaTity expetienced a peri(Id of heightened S¢￿tinY following a ChaTity Coinmi55ion enquiry. The enquiry concluded in March 2026 with eertain recominendations made which the Trustees are now addressing. FuMdr#isiMg Campaign Tlie charity held a fundraising campaign in July 2025. Some pledged donations had not been received by 31 December 2025, and receipts froin the CdlllP(ii¥n continued ii)to 2026. Reserve5 policy The Trustees have examined the charity's requirements for rese￿eS in light of the mait] risk5 to the organisation. It has e5tabli5hed a policy whereby the unrestricted funds not cominitted or invested in taiibTible fixed assets held by the charity should be between 3 and 6 months of the expenditUTe. Budgeted expendituie for 2026 is £1.2m and therelort the target is £300,000 to £600,0(10 in unrestricted reserve funds. The reserves are needed to meet the working capital requirements of the charity and the Management Committee are confident that at this level they would be able to continue the current actii'ities of thc charity in thc cvcnt of a significant drop in funding. Thc prcscnt Icvcl of unrcstrictcd rc8crvc% availablc to thc charity of £284,000 therefore falls short of thi5 tsrget level. MARS I ANNUAL REPORT 2025 18

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG LTD TRUSTEES, ANNUAL REPORT. YEAR ENDED 31 DECEMBER 2025 TRUSTEES. RESPONSIBILITIES STATEMENT The trustees, who are also directors for the purposes of company law, are responsible for preparing the trustees, report and the financial %tatcmcnts in accordance with applicablc law and Unitcd Kingdom Accounting Standard% (United Kingdom Generally Accepted Accounting Practice). Company law requires the eharity trustees to prepare financial statements for each year which give a true and fair view of the state of affair5 of the charitable company and the illcoming resources and application of resources, including the income and expenditure, for that period. In prcparing thc%c financial %tatcmcnt8, thc tru%tcc% arc rcquircd to.. select suitable accounting policies and then apply them consistently,. observe the meth(Kls and principles in the applicable Chaiities SORP., ake judgments and accounting estin￿teS that are reasonable and prndent- prcparc thc financial.%tatcmcntq on thc going conccrn ba8i% unlc$8 it is inappropriatc to prcsumc that thc charity will contit]ue in business. The trustees are responsible for keeping adequate accounting re¢ords that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the chaTity and et]able them to ensure that the financial sthtements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Ch[￿ltY aiid hence foi takin¥ reabunable steps foi the prevention aiid detectiun of Iiuud aiid Other itTe¥ulL￿lt]cS. In so far as the trllstees are aware.. there is no relevant audit inforniation of which the charitable company's auditors are unaware., and the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit infom)ation and to estsblish that the auditors are aware of that inforniation. The auditors, Cohen Amold were appointed on 27 October 2025 and will be proposed for re-appointment at the forthcoming Annual General Meeting. AUDITOR Each of the persons who is a trustee at the date ol'approval of this report confim)s that". 50 far a5 they are aware, there 15 no relevant audit infolynation of which the charity'5 auditor is unaware.. and they have taken all steps that they ouglit to haN'e taken as a trustee to make themselves aware of any relevant audit infom]ation and to establish that the charity's auditor is aware of that infoTmation. Thc auditor 1% dccmcd to havc bccn rc-appointcd in accordancc with %cction 487 of thc Companics Act 2006. SMALL COMPANY PROVISIONS This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies cxcmption. 2911012026 The twstees, annual report was approved on .............................. and signed on behalf of the board of trustees by.. Mr H Giunfeld gn•d by.. Trustee b82cl764E￿24A5 MARS I ANNUAL REPORT 2025 19

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MARS ORG. LTD YEAR ENDED 31 DECEMBER 2025 OPINION We have audited the financial statements of MARS ORG. LTD (the 'charit) ) for the year ended 31 December 2025 which comprise the statement of financial aCtI￿.1t]eS (including income and expenditure account), statement of financial position, statement of cash tlow's and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable laiv and United Kingdoin Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland {United Kingdom Generally Accepted Accounting Practice). In our opinion the financial statements.. give a true and fair i'iem, of the state of the charity's affairs as at 31 Deceinber ?025 and of its incoiniiig rcsources and application of resources. including its incoine and expcnditure, fort]ie }'ear then ended; have been properlv prepared in accordance with United Kingdom Generally Accepted Accounting Practice- havc bccn prcparcd in accordance with th¢ requirctncnts of the Cotnpanics Act 2006 and the Charities Act 2011. BASIS FOR OPINION W¢ ¢ondu¢led our audit in a¢cordaiice witli Intemalional Standards on Auditing {UK}{ISAs (UK)} and &ppli¢able law. Our responsibilities under tliose standards are fiirtlier described in the aiiditor's resw)nsibiliii¢s for the audit of the finan¢ial slatem¢nis section of our report. We are ind¢p¢ndent of the charity. in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including th¢ FRC s Ethi¢al Standard, and w¢ hav¢ fulfilled OLir other ¢thi¢al reswnsibiliiies in accordance with these requireinents. We believe that the audit evidence we have obtained is sufficient and appropria(e to provid¢ a basis for our opinion. CONCLUSIONS RELATING TO GOING CONCERN In auditiiig the financial statements, Ive have concluded that the ti'ustees, use of the going concern basis of accounting in the preparation ot the financial statements is appropriate. Based on the workwe have perfom]ed, we have not identitied an}, material uncertainties relating to eiwents or conditions that. individually or collectiiwely, ma}, cast significant doubt on the Compan￿ s ability to continue as a going concern for a period of at least twelve months from ivhen the financial statements are authorised for issue. Our responsibilities and tl)e respx)nsibilities ot the trustees with respect to goiiig coiiccrn are described in the rclcvant sections of this rcpx)rt. MARS I ANNUAL REPORT 2025 20

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MARS ORG. LTD YEAR ENDED 31 DECEMBER 2025 OTHER INFORMATION The other infom]ation comprises Ihe infom)ation included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other infom)ation. Our opinion on the financial statements does not cover the other infom)ation and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materiall)w inconsistent with the financial stateinents or our knoivledge obtained in the audit or otheThi'ise appears to be materially tlllSStated. If ive identify such material inconsistencies or apparent material misststetnents, we are required to determine ￿'hether there is a material Iiiisstatement in the financial statements or a material tlllSStatcmellt of the otlier inforniation. If, based on tl)e work we have perfotincd, concludc that there is a material tnisstateinent of this other infotination, we are required to report that fact. We have nothing to report in this regard. OPILYIOIYS OLY OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006 In our opinion, bascd on the work undcrtakcn in th¢ course of th¢ audit.. the information given in rhe trustees, report for tlie fiiian¢ial year for whicli the financial statements are prepared is consistent with the financial stateiiients; and the trustees, report has been prepared in accordance with appli¢able legal reqiiirements. MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION In (he light ofthe knowl¢dgeand understanding of the charity and its environmentobtained in the Course of the audit, we have not identified material misstatements in the trustees, report. We have nothing to re]x)rt in respect of the follo￿.]ng matters in rela(ion to which the Companies Act 2006 and the Charities Act 201 I requires us to report to )'ou if, in our opinion.. adequate accounting records haN'e not been kept, or retums adequate for our audit have not been received from branches not visited by us; or the financial statements are not in agreement with the accounting records and returns; or certain disclosures of irustees, remuneration specified by laiv are not made,. or we have not received all the infom]ation and explanations we require for our audit; or the trustees were Iiot eiititled to prcpare the finaiicial statctnciits iii accordaiice w'ith thc small coinpanies regitne and take advanlage of the sinall companies, exeiiiptions in preparing the director5, report and from the requiretnent to prepare a strategic report. MARS I ANNUAL REPORT 2025 21

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MARS ORG. LTD YEAR ENDED 31 DECEMBER 2025 RESPONSIBILrrIES OF TRUSTEES As explained more fully in the trustees, responsibilities statement, the trustees (who are also the directors for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and tair view, and for such internal control as the trustees detem)ine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due lo traud or error. In preparing the financial slatements, the trustees are responsible for assessing the charity's ability, to continue as a going concern, disclosing, as applicable, matters related io going concern and using the going concern basis of accounting unless the trustees eiiher intend to liquidate the charity or to cease operations. or have no realistic alternative but to do so. AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FIIYANCIAL STATEMETr4TS Our objectives are to obtain reasonable assurance aboutwhetherthe financial statements a5 a whole are frcc from matcrial misstatcinciiL whcthcr duc to fraud or crror. and to Issuc an auditor s report that includes our opinion. Rcasonablc assurance 15 a high level of assurance. but is not a guarantee that an audit conducted in aLcordance with ISAS {UK} will aliva)'s dctcct a matcrial misstat¢tn¢nt whcn it exisls. Missiatemenls cali arise from fraud or error aiid are considered material if, individuall). or in the &ggregat¢, they could rcasonably be expccted to influence the ecoiioinic decisions of uscrs taken on rhe basis of these financial statements. Irregulariiies, including fraud, are instances of non-¢omplian¢e wilh laws and regulations. We design procedures in line with our respoiisibilities, oiitlined above, to detevl material misstalemeiits in respect of irregulariti¢s, including fraud. Th¢ ext¢ni to which our pro¢¢dur¢s are ¢apable of det¢ciing irregularities, including fraud is detailed beloiv.. We obtained an understanding of the legal and regulatory frameworks that are applicable to the company, and deterniined that the most relevant to the presentation of the financial statements are those that relate to the reporting legislation (UK GAAP and the Companies Act 2006), the relevant tax regulations in the United Kingdom, the Landlord and Tenant Act, the UK General Data Protection Regulation (GDPR), Health & Safety Regulations and the Bribery Act. We understood ho￿. the company is complying ivith those frameworks through disciissioii ivith the trustees and senior management, and by identify'ing the company's policies and procedures regarding compliance with laTh's and regulations. We also identified those members of management ivho l)ave tlie primary respoiisibility for ensuring compliance with laws and regulations, and for reporting an}, known instances of non-compliance to the trustees. We communicated tl)ese identified fraiiiew'orks aii)ongst our audit teain and remained alert to any indications of non-compliance throughout the audit. We ensured that the engagement teatn had sufficientcotnpetenceand capability to identify or recognise non-compliance with law's and regulations. We discussed with the trustees and senior managemenl the policies and procedures regarding cotllpliaiicc M'ith th¢sc Icgal and regulatory fratncworks. W¢ asscsscd thc susccptibilitv of the coillpany's financial statcmellts to Inaterial mis5tatcinent, including how fraud tnighi occur, by reviewiiig the cotnpan} s idcntified risks and enquiry with ihe trustccs and senior maiia¥cin¢nt during thc planning and finalisation phas¢s of our audit. Thc susceptibility to such material misstaleinent was detemiined to be low. MARS I ANNUAL REPORT 2025 22

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MARS ORG. LTD YEAR ENDED 31 DECEMBER 2025 Based on this understanding we designed our audit procedures to identify non-compliance with the identified legal and regulatory frameworks, which ￿'ere part of our procedures on the related financial statement items. Our procedures included reviewing the company's internal controls policies and procedures, re￿.leThing the minutes of board meetings and correspondence with regulatory bodies includiiig HMRC, testing trai)sactions outside the normal course of the business and journal entries, and discussions with the trustees and senior management. Owing lo the inherent limitations of an audit, there is an una￿0]dable risk that we tnay not have detected some Inaterial Inisstatements in tlie financial stateinents, even though we have properl). planned and performed our audit in accordance with auditing standards. For exatnple, the further retnoved non- cotnpliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, thc Icss likcly the iiihcrcntl). litnitcd procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irrcgularitics, as tlicsc may involvc collusion, forgery., intentional oinissions, misrcprescntations, or thc override of intcrnal controls. We are not responsible for preventing non-cotnpliance and cannot be cxpcctcd to dct¢ct iion-coinpliancc with all laws and regulations. As part of an audit in accordanc¢ with ISAS (UK), we cxcrcisc profcssional judgtllent and maintain professional scepticisin throughout the audit. We also: Ideiilify and assess tlie risks of material misstatemeiil of the fiiiaii¢ial starements, whetlier due to fraud or etTor, design and perforin aiidit prc)cedures respc)nsive to those I'isks, and obtain audit evid¢n¢e that is sutTi¢ienl and appropriat¢ to provid¢ a basis for our opinion. The risk of not detecting a material misstatement resulting from fraiid is higher than for one ￿sUIting from error, as fraud masj involve ¢ollusion, forg¢ry, inl¢ntional omissions, misrepresentations, or the overrid¢ of internal control. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made b}, the trustees. Conclude on the appropriateness of the trustees, use of the going concern basis of accounting and, b ased on ihe audit evidence obtained. whether a tnaterial uncertainty exists related to events or conditions that Inay cast significant doubt on the charity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures li) I1)e financial statetllents or, if such disclosures are inadequate: to modify our opiiiion. Our conclusions are based on the audit evidence obtsiiied up to the datc auditor's report. However, future events or conditions may cause the charity to cease to continue as a going concern. Evaluatc thc overall preKntatlOll, Structure and colltcnt of thc financial statcmcnts, including thc disclosure5, and whether the financial stateinents rcpresent the undcrlying transactions and events in a mann¢r t])at acl)icvcs fair prcscntation. MARS I ANNUAL REPORT 2025 23

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF MARS ORG. LTD YEAR ENDED 31 DECEMBER 2025 We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant alldit findings, including any significant deficiencies in internal control that we identity during our alidit. USE OF OUR REPORT This report is made solely to the charity's members, as a body, in accordance with section 144 ot the Charities Act 2011 and regulations made under section 154 of that Act. Our audit w'ork lias been undertaken so ihat ive might state to the charitv's members those matters we are required to state to tl)ein in an auditorfs report and for no other purpose. To tlie fullest extent permitted by law, we do not accept or assutne responsibililv to anyone other than the charity and the charity's members as a body, for our audit work, for this reporL or for the opinions we have fortned. Do¢US￿nId ty.. 8C6977A458CD499 New Burlington House 1075 Finchley Road London NWII OPU David Goldberg (Senior statutory auditor) Cohen Arnold Chartered accountants & statutory auditor 2911012026 MARS I ANNUAL REPORT 2025 24

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE STATEMENT OF FINANCIAL ACTIVITIES (INCLUDIIYG INCOME AND EXPELNDITURE ACCOUNT) YEAR ENDED 31 DECEMBER 2025 2025 Restricted funds Total funds Total fi]nds 2024 Unrestricted funds Note Income and endowments Donations and legacies Investment iiicome 1,478,901 1,959 247,171 1,726,072 1.959 1,594,668 1,019 Total income 1,480,860 247,171 1,728,031 1,595,687 Expenditure Expei)diture on ￿lSing funds.. Cosls of raising donations and Icgacics Expenditure on charitable activities Totll expenditure (209,744) (209,744) ( l J9,943) 9,10 11,312,870) (205,189) (1,518,059) {1,4JO,138) (1,522,614) (205,189) (1,727J103) (1,570,081) Net income and net movement in funds (41,754) 41,982 228 25,606 Reconcilialion of funds Total funds brought form'ard Total funds earried forward 326,559 57,471 384,030 358,424 284,80) 99,453 384258 384,030 The stat¢menl of finan¢ial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities. Th¢ notes Dn pages 28 to 35 fonn part nf these financial sl¢it¢rn¢nLs. MARS I ANNUAL REPORT 2025 25

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE STATEMENT OF FINANCIAL POSITION 31 DECEMBER 2025 2025 2024 Note FIXED ASSETS Tangible fixed assets CURRENT ASSETS Debtors Cash at bank and in hand 16 216281 224.828 17 30,420 184,065 197,883 214,485 197,883 CREDITORS: amounts falling due within one Year 19 (29J50) {16,460) NET CURRENT ASSETS 185,135 181,423 TOTAL ASSETS LESS CURRELYT LIABILITIES 401,416 406,251 CREDITORS: amounts falling due after more than one vear 20 (17,158) {22,221) NET ASSETS 384258 384,OJO FUNDS OF THE CHARITY Restricted funds Llnreslricled funds 99,453 284,805 57,471 326,559 Total charity funds 21 384258 384,030 These finan¢ial statements have been pr¢par¢d in a¢cordanc¢ wilh the provisions applicable to companies subject 10 the small companies, regime. These financial statements were approved by the board of trustees and authorised for issue on 2911012026 , and are signed on behalf of the board by.. S*n•dby'. riin Trusfre Th¢ notes Dn pages 28 to 35 fonn part nf these financial sl¢it¢rn¢nLs. MARS I ANNUAL REPORT 2025 26

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE STATEMENT OF CASH FLOWS YEAR ENDED 31 DECEMBER 2025 2025 2024 Note CASH FLOWS FROM OPERATING ACTIvrrIES Net income 228 25.606 AdjuslmL)nl.%]or.' Depreciation of tangible fixed assets Other interest receivable aiid similar income Interest payable and similar charges Changes iii.. Trade and other debtors Trade and other creditors 8547 (1,959} 1,182 1,716 (1,019) 2,709 {30,420} 12088 49,307 (5.037) 83,282 Cash generated from operatioiis Interest paid Interest received (9,534} (1,182) (2,709) 1,019 Net cash (used in)Ifrotll operating activities (8,757) 81,592 CASH FLOWS FROM INVESTING ACTIVITIES Purchasc of tangibl¢ assCtS Net cash used in iiivesting activities (3,236) (3,236) CASH FLOWS FROM FINANCING ACTIVITIES Pro¢¢¢ds from botTowings Net cash used in financing a¢tiviti¢s (5,064) (5,064) (4,549) (4,549) NET (DECREASE)IINCREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR {13,821} 197083 73.807 124.076 CASH AND CASH EQUIVALENTS AT END OF YEAR 18 184,062 197.883 Th¢ notes Dn pages 28 to 35 fonn part nf these financial sl¢it¢rn¢nLs. MARS I ANNUAL REPORT 2025 27

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMEINTS YEAR ENDED 31 DECEMBER 2025 GENERAL INFORLIL4TION The charity is a public benefit entity and a private compan}, limited by guarantee, registered in England and W'ales and a registered cliarity in England and Wales. The address ot the registered office is New Burlington House. 1075 Finchley Road, London, NWI I OPU, United Kingdom. STATEMENT OF COMPLIANCE These financial statements have been prepared in compliai)ce witl) FRS 102, 'The Fii)ai)cial Reporting Standard applicable in the UK and the Republic of Ireland,, the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP {FRS 102)) and the Companies Act 2006. ACCOUNTING POLICIES BASIS of preparation Thc financial statcmcnts havc bccn prcparcd on the historical cost basis. Thc financial statements arc prcparcd in stcrlin¥y which is the functional currency of th¢ entity. Going concern There are no mat¢rial uncertainties abour rhe ¢harity's ability to Continue. Judgements and key sources of estimation uncertainty The preparation of th¢ finan¢ial stat¢m¢ntq r¢quires man&g¢m¢nt to make judgements, ¢stimates a assiimptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including exp¢ctations of future ¢v¢nls that are believed to be reasonable under the circumstances. There have been no material adjustments based on estimations and assumptions during the financial year. Fund aceounting General unrestricted funds comprise the accurllulated surplus or deficit on incoine and expenditure account. Thev are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity. Restricted funds are funds subject to specific restricted conditions imposed by donors. Dc5ignatcd funds arc funds which have bccn sct at thc di5crction of the Trustccs for specific purposes. Therc are no designated funds as at the Balance Sheet date. Incoming resources All donations arc rccognis¢d in thc statcmcnt of financial activitlcs (SOFA} of thc charity whcn received. All other income is recognised on a receivable basis. MARS I ANNUAL REPORT 2025 28

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿? YEAR ENDED 31 DECEMBER 2025 ACCOUNTING POLICIES {cortiiniied) Resourees expended All expenditure is classified urider the Charity's principal categories of charitable and other expenditure and by the type of expense. Tangible assets Tangible assets are initially recorded al cost, and subsequently stated at cost less any accumulated depreciation and iinpairment losses. Any tangible assets carried at revalued aii)ounts are recorded at the fair value at the date of revaluation less any subsequent accutnulated depreciation and subseqiient acciimulated iiiipairment losses. An increase in the catrying ainount of an asset as a resiilt of a revaliiation, is recognised in other recogni5ed gains and 105ses, unless it reverses a charge for iiiipairtnent t]iat has previously been recognised as expenditure within the statement of financial aclivities. A decrease in the carrying amount of an a5SCt as a result of rcvaluation, is rccogniscd in othcr rcco¥niscd gains and Iosscs, except lo which it offscts anj. previous revaluation gain, in which c&se the loss is shown i¥ithin other recognised gains and losses on the statcmcnt of financial activities. Depreciation Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the us¢ful economi¢ life of that asset as follows.. Fixlur¢s and filliiigs Coinputer equipment FinaDeial instruments 15 % r¢ducin£ balanc¢ 330/0 reducing balance A financial asset or a financial liability is recognised only when the entit! becomes a party to the contractual provisions of the insirument. Basic financial instruments are initiall)w recognised at the amount receivable or payable including any related transaction costs, unless the arrangement constitutes a financing transaction, w,here it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Ciirrent assets and current liabilities are subsequently tneasured at the cash or other consideration expected to be paid or received and not discounted. LIMITED BY GUARANTEE The charity is a company limited by guarantee and has no share capital. The liability of each ttwstee in thc cvciit of winding up is litllitcd to £ l. MARS I ANNUAL REPORT 2025 29

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿? YEAR ENDED 31 DECEMBER 2025 DONATIONS AND LEGACIES Unrestricted Funds Restricted Total Funds Funds 2025 DONATIONS Donations 1,440,921 247,171 1,688,092 GRANTS Grants 37,980 37,980 1,478,901 247,171 1,726,072 Unrestricled Funds Restricled Total Funds Funds 2024 DOLYATIOP4S Donations 1,292,572 282,9JO 1,575,502 GRANTS Grants 19,166 19,166 1,311,738 282,930 1,594,668 ANALYSIS OF GRANTS RECEIVED Donations r¢¢¢iv¢d, includ¢d in the abo￿¢, ar¢ as follows.. 2025 2024 Spe¢ial case fund 247,171 282.930 INVESTMENT INCOME Unrestricted Total Funds Unrestricted Total Funds Funds 2025 Funds 2024 Bank interest receivable 1,959 1,959 1,019 1,019 COSTS OF RAISING DONATIONS AND LEGACIES Unrestricted Total Funds Unrestricted Total Funds Funds 2025 Funds 2024 Fundraising costs 209,744 209,744 139,943 139,943 MARS I ANNUAL REPORT 2025 30

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿? YEAR ENDED 31 DECEMBER 2025 EXPENDITURE ON CHARrrABLE ACTIVITIES BY FUND TYPE Unrestricted Funds Restricted Total Funds Funds 2025 Charitable activities Support costs 1,269,960 42,910 205,189 1,475,149 42,910 1,312,870 205,189 1,518,059 Unrestricted Funds Restricted Total Funds Funds Charitable activilies Support costs 1.071,074 40,366 318,698 1,389,772 40,366 1.111,440 318,698 1,430,lJ8 10. EXPENDITURE ON CHARITABLE ACTIVITIES BY ACTIVITY TYPE Activities undcrtaken dire¢tly Support costs Total funds 2025 Total fund 2024 Charitable activities Govemance costs 1,475,149 30,928 11,982 1,506,077 11,982 1,413,685 16,453 1,475,149 42,910 1,518,059 1,430,138 11. ANALYSIS OF CHARITABLE ACTIVITIES 2025 2024 Charitable Activities Grants 10 institutions Special case fund Medical Support Holiday (Yom Tov) clinics Health am'areness Sustenance packages Medical research 404207 106219 280282 302,722 21,428 446,897 401.430 172,413 26.899 84,141 96.486 161,506 96,030 205,189 1,475,149 1,389,772 MARS I ANNUAL REPORT 2025 31

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿? YEAR ENDED 31 DECEMBER 2025 12. ANALYSIS OF SUPPORT COSTS Charitable activities Total 2025 Total 2024 Finance costs Govemance costs Legal and professional fees Depreciation 1.182 10,800 22,381 8,547 1,182 10000 22J81 8547 2.709 13,744 12.197 11,716 42,910 42,910 40,366 13. NET INCOME Net income is stated after charging/(crediting)= 2025 2024 Depreciation of tangible fixed assets Fees payable for the audit of the financial statements 8,547 10,800 11,716 13,744 14. STAFF COSTS 2025 2024 Wages and salaries Social security costs 276260 6.537 261.685 4.326 282,797 266,011 The average Inonthly number of employees during the year was 29 (2024.. 27). No salaries of £60.000 or over ￿'¢re paid during the year. 15. TRUSTEE REMUNERATION AND EXPENSES No remuneration or oiher benefits from ¢mploym¢nt with the charity or a related entity w¢r¢ r¢¢eiv¢d by the trustees. MARS I ANNUAL REPORT 2025 32

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿? YEAR ENDED 31 DECEMBER 2025 16. TANGIBLE FIXED ASSETS Land and Fixtures and buildings fittings Equipment Totgl Cost At l January 2025 and 31 December 2025 187.703 45,801 69,694 303,198 Depreciation Ai l January 2025 Charge for the year At 31 December 2025 25,221 3,087 53,149 5,460 78,370 8,547 28,308 58,609 86,917 Carryillg amount At 31 December 2025 187,703 187,703 17,493 20,580 11,085 16,545 216,281 224,828 At 31 Dcccmbcr 2024 17. DEBTORS 2025 2024 Other debtors 30,420 18. CASH AND CASH EQUIVALENTS Cash and cash equivalents comprise the folloiving.. 2025 2024 Cash at bank and in hand Bank overdrafts 184,06) {3) 184,062 197,883 197.883 19. CREDrroRS: iimounts f31lling dlle ￿￿thIn one ye3ir 2025 2024 Bank loans and overdrafts Social security and other taxes Other creditors 4,503 7,764 17,083 4,500 1,998 9,962 29,350 16,460 20. CREDrroRS: amounts falling due after more than one year 2025 2024 Bank loans and overdrafts 17,158 2?,221 MARS I ANNUAL REPORT 2025 33

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿? YEAR ENDED 31 DECEMBER 2025 21. ANALYSIS OF CHARITABLE FUNDS Unrestricted funds Atl January 2025 At31 Deeembcr 2025 Income Expenditure General funds 326.559 1,480,860 (1,522.614) 284,805 Atl January 2024 At31 Deceinber 2024 Income Expenditure General funds 265,185 1,312,757 {1,251,38i) 326,559 Restricted fullds Atl January 2025 At31 December 2025 Income Expcnditurc Restricted Fund 57,471 247,171 (205,189} 99,453 At I January 2024 At31 December 2024 In¢ome Expenditure Restricted Fund 282,930 (J18,698} 57,471 22. ANALYSIS OF NET ASSETS BETWEEN FUNDS Unrestricted FLinds Restricted Total Funds Funds 2fj25 Tangible fixed assets Current assets Creditors less than l year Creditors greater than l year 216,281 115,032 (29,350) (17,158) 216,281 214,485 (29J50} (17,158} 99,453 Net 3issets 284,805 99,453 384,258 Unrestricted Fuiids Restricted Total Funds Funds 2024 Tangible fixed assets Current assets Creditors less than l year Creditors greater than l year Net asset5 224,828 140,412 (16.460) (22.221) 326,559 224,8?8 197,883 (16,460) {22.221) 57,471 57,471 384,030 MARS I ANNUAL REPORT 2025 34

Docusign EnvelopÈ ID". 42E7C64E-386U4C1-8361-66ED4F05CE20 MARS ORG. LTD COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS (con11n￿e￿? YEAR ENDED 31 DECEMBER 2025 23. ANALYSIS OF CHANGES IN NET DEBT At At l Jan 2025 Cash flows 31 Dec 2025 Cash at bank and in hand Bank overdrafts Debt due within one year Debt due after one year 197,883 (13,818) {3) 184,065 {3} (4,499) (17,158) (4.500) {22,221) 5,063 171,162 (8,757) 162,405 24. RELATED PARTIES There have been no related party transactions in the reporting period that require disclosure. MARS I ANNUAL REPORT 2025 35

Docusign Envelope ID". 42E7C64E-386944C1-8361-66ED4F05CE20 MedK81A<￿aCY & Refernalserv. THANK I You To our partners, supporters, specialists and community. One Call. Expert Support. Better Outcomes. Medical Advocacy & Referral Service Trustees, Annual Report 2025